Companies /Healthcare

Pelthos Therapeutics Inc.

NYSE MKT: PTHS Biotechnology
$6.81
▼ $0.03 (−0.44%) today
Markets open · 4:02pm ET

PTHS at a Glance

Valuation
Market cap
$28.1M
Profitability
Revenue (TTM)
$51.3M
Profit margin
-152.2%
EPS (TTM)
$-23.86
Price
52-week range
$7 – $32
Street target
$41.43

Headquartered in Durham, NC Fiscal year ends December NYSE MKT: PTHS pelthos.com

About Pelthos Therapeutics

Pelthos Therapeutics Inc. (NYSE American: PTHS) is a commercial-stage biopharmaceutical company building a portfolio of differentiated products for cutaneous infectious and skin diseases.

- **Zelsuvmi (berdazimer) topical gel, 10.3%:** its lead marketed product and main revenue source. It is a prescription therapy approved for at-home use by patients, parents and caregivers to treat molluscum contagiosum.
- **Xepi (ozenoxacin) Cream, 1%:** an FDA-approved topical treatment for impetigo, with launch targeted for the first quarter of 2027.
- **Xeglyze (abametapir):** an FDA-approved topical treatment for head lice, with launch targeted for the third quarter of 2027.
- **Nitricil:** a proprietary technical and manufacturing platform.
- **Other revenue:** modest license and collaboration revenues.

The company markets to dermatology, pediatric dermatology and pediatric prescribers. Zelsuvmi has commercial formulary coverage of 127 million lives and broad Medicaid coverage.

In October 2026 Pelthos agreed to merge with Castle Creek Biosciences, a late-stage developer of redosable fibroblast-based cell and gene therapies. Castle Creek's lead candidate D-Fi targets dystrophic epidermolysis bullosa. The combined company would span marketed, launch-stage and late-stage assets focused on serious diseases affecting the skin.

Pelthos is financed partly through a senior secured term loan facility with Horizon Technology Finance and convertible notes. Updated

PTHS Coverage

Frequently Asked Questions

What does Pelthos Therapeutics do?

Pelthos Therapeutics Inc. (NYSE American: PTHS) is a commercial-stage biopharmaceutical company building a portfolio of differentiated products for cutaneous infectious and skin diseases. - **Zelsuvmi (berdazimer) topical gel, 10.3%:** its lead marketed product and main revenue source.

What is the PTHS stock price target?

The Wall Street consensus 12-month price target for PTHS is $41.43.